Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Antimicrobial peptides (AMPs), in addition to their antibacterial properties, are also chemotactic and signalling molecules that connect the innate and adaptive immune responses. The role of AMP [alpha defensins,
LL-37
, a cathepsin G-derived peptide (CG117-136), protegrins (PG-1), polymyxin B (PMX) and LLP1] in modulating the respiratory burst response in human and murine macrophages in the presence of bacterial endotoxin [
lipopolysaccharide
(
LPS
) or lipooligosaccharide (LOS)] was investigated. AMP were found to neutralize endotoxin induction of nitric oxide and TNFalpha release in macrophages in a dose-dependent manner. In contrast, macrophages primed overnight with AMP and LOS or
LPS
significantly enhanced reactive oxygen species (ROS) release compared with cells primed with endotoxin or AMP alone, while no responses were seen in unprimed cells. This enhanced ROS release by macrophages was seen in all cell lines including those obtained from C3H/HeJ (TLR4-/-) mice. Similar effects were also seen when AMP and endotoxin were added directly with zymosan to trigger phagocytosis and the respiratory burst in unprimed RAW 264.7 and C3H/HeJ macrophages. Amplification of ROS release was also demonstrated in a cell-free system of xanthine and xanthine oxidase. Although AMP inhibited cytokine and nitric oxide induction by endotoxin in a TLR4-dependent manner, AMP and endotoxin amplified ROS release in a TLR4-independent manner possibly by exerting a prolonged catalytic effect on the ROS generating enzymes such as the NADPH-oxidase complex.
...
PMID:Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. 1609 13
Defensins and cathelicidins (
LL-37
) are major antimicrobial peptides (AMPs) of the innate immune system of the human skin. In normal non-inflamed skin these peptides are negligible, but their expression can be markedly increased in inflammatory skin disease such as psoriasis. We designed this study to identify the expressions of
LL-37
in normal human keratinocyte (NHK) and HaCaT cells after exposure to stimulants and to investigate difference of
LL-37
expression accompanied with cell differentiation status, and come to understand difference of susceptibility to infection in atopic dermatitis and psoriasis. Expressions of
LL-37
in NHKs and HaCaT cells were evaluated by using RT-PCR, Western blotting, and immunohistochemical (IHC) staining at 6, 12, and 24 hr post stimulation after exposure to Ultraviolet B irradiation and
lipopolysaccharide
. And expression of
LL-37
in skin biopsy specimens from patients with atopic dermatitis and psoriasis was determined by immunohistochemical analysis. In time-sequential analyses of
LL-37
expression revealed that
LL-37
was expressed in NHKs, but not in HaCaT cells. IHC analysis confirmed the presence of abundant
LL-37
in the epidermis of psoriasis. Therefore we deduced that expression of
LL-37
is affected by UV irradiation, bacterial infection, and status of cell differentiation.
...
PMID:Expression and modulation of LL-37 in normal human keratinocytes, HaCaT cells, and inflammatory skin diseases. 1610 Apr 59
New peptides for
lipopolysaccharide
(
LPS
) and lipoteichoic acid (LTA) neutralization in upper respiratory tract infections were developed and evaluated in terms of efficacy and safety for application in humans. Based on the sequence of the human antimicrobial peptide
LL-37
we developed and investigated length variants, substitution analogues and modifications to stabilize the peptides to prevent enzymatic degradation and to improve efficacy. The most promising peptide appears P60.4, a 24 amino acid peptide with similar efficacy as
LL-37
in terms of
LPS
and LTA neutralization and lower pro-inflammatory activity. In addition, the acetylated and amidated version of this peptide shows no toxicity and displays higher or equal antimicrobial activity compared to
LL-37
.
...
PMID:Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. 1627 47
Binding of
lipopolysaccharide
(
LPS
) to macrophages results in proinflammatory cytokine secretion. In extreme cases it leads to endotoxic shock. A few innate immunity antimicrobial peptides (AMPs) neutralize
LPS
activity. However, the underlying mechanism and properties of the peptides are not yet clear. Toward meeting this goal we investigated four AMPs and their fluorescently labeled analogs. These AMPs varied in composition, length, structure, and selectivity toward cells. The list included human
LL-37
(37-mer), magainin (24-mer), a 15-mer amphipathic alpha-helix, and its D,L-amino acid structurally altered analog. The peptides were investigated for their ability to inhibit
LPS
-mediated cytokine release from RAW264.7 and bone marrow-derived primary macrophages, to bind
LPS
in solution, and when
LPS
is already bound to macrophages (fluorescence spectroscopy and confocal microscopy), to compete with
LPS
for its binding site on the CD14 receptor (flow cytometry) and affect
LPS
oligomerization. We conclude that a strong binding of a peptide to
LPS
aggregates accompanied by aggregate dissociation prevents
LPS
from binding to the carrier protein lipopolysaccharide-binding protein, or alternatively to its receptor, and hence inhibits cytokine secretion.
...
PMID:Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. 1629 30
Corneal neovascularization can be induced by a severe ocular infection, injury or immunological diseases. The vascular endothelial growth factor (VEGF) is the main cytokine involved in this phenomenon, inducing angiogenesis from the vascularized ocular tissues. As the limbal tissue is located between conjunctival and corneal tissues, we suggest that the limbal cells are participating in the production of VEGF induced by bacterial components as
LPS
. In this work, RT-PCRs and immunoblots were used to investigate the expression of VEGF and other pro-angiogenic genes in primary cultures of human limbal fibroblasts (PCHLF) treated with
lipopolysaccharide
(
LPS
) from Escherichia coli. We found that the expression of VEGF was initiated at 6 h and reaches its highest expression at 72 h after stimulation with
LPS
. Up-regulation of toll-like receptor 4 (TLR4) after 3 h of treatment was also observed.
LPS
-induced the expression of VEGF in a dose-dependent manner, and the blocking of TLR4 with an anti-TLR4 antibody prevented VEGF expression. We also analyzed the molecules that modulate VEGF expression.
LPS
did not induce the up-regulation of
LL-37
nor the hypoxia induced factor 1 alpha (HIF-1alpha) mRNA expression, however, an up-regulation of interleukin 13 receptor alpha 1 (IL-13Ralpha1) and interleukin 4 receptor alpha (IL-4Ralpha) were observed after 3 and 12 h of stimulation, respectively. The expression of interleukin 13 did not change throughout the treatment. These results suggest that TLR4, IL-13Ralpha1 and IL-4Ralpha induced by
LPS
in PCHLF could be playing an important role in the corneal neovascularization.
...
PMID:Lipopolysaccharide from Escherichia coli induces the expression of vascular endothelial growth factor via toll-like receptor 4 in human limbal fibroblasts. 1699 97
Cationic antibacterial peptides (ABPs) are secreted in the airways and function in the first line of defence against infectious agents. They attack multiple molecular targets to cooperatively penetrate and disrupt microbial surfaces and membrane barriers. Antibacterial properties of ABPs, including cathelicidin
LL-37
, are reduced in cystic fibrosis (CF) airways as a result of direct interaction with DNA and filamentous (F)-actin. Microscopic evaluation of a mixed solution of DNA and F-actin, after the addition of rhodamine-B-labelled
LL-37
peptide, revealed the presence of a bundle structure similar to that present in CF sputum. Analysis of CF sputum after centrifugation showed that
LL-37
was mostly bound to components of the pellet fraction containing DNA, F-actin and cell remnants. Factors that dissolve DNA/actin bundles and fluidise CF sputum, such as Dornase alfa (recombinant human DNase I), gelsolin, polyaspartate or their combinations, increased the amount of
LL-37
peptide detected in the supernatant of CF sputum. The presence of the bacterial endotoxin
lipopolysaccharide
(
LPS
) in CF sputum and the ability of
LPS
to inhibit the antibacterial activity of
LL-37
suggests that inactivation of
LL-37
function in CF sputum partially results from its interaction with
LPS
.
LL-37
-
LPS
interaction was prevented by an LPS-binding protein (LBP)-derived peptide known for its ability to neutralise
LPS
, whereas LBPW91A, a mutant peptide that lacks ability to bind
LPS
, had no effect. A combination of factors that dissolve DNA/filamentous-actin aggregates together with
lipopolysaccharide
-binding agents may represent a potential treatment for the chronic infections that occur in cystic fibrosis airways.
...
PMID:Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. 1740 Aug 74
Gingival innate immunity has been studied by using biopsies and normal or transformed epithelial cell monolayers. To overcome individual biological variabilities and as a physiological alternative, we have proposed using a reconstructed tissue equivalent. In this study, we investigated the functionality and the stage of differentiation of a reconstructed human gingival epithelium. We also characterized this epithelium at the molecular level to investigate its differentiation stage compared with native human gingival epithelium. The expression levels and localization of markers related to proteins and lipids of well-differentiated stratified epithelium, such as cytokeratins, cornified envelope proteins and enzymes, or to factors in lipid synthesis and trafficking were examined. Immunohistochemistry revealed similar localization patterns in both types of epithelia and mRNA quantification showed a close resemblance of their expression profiles. We further revealed that, like native gingiva, reconstructed gingival epithelium was able to respond to pro-inflammatory or
lipopolysaccharide
stimuli by producing antimicrobial peptides hbetaD-2, hbetaD-3 or
LL-37
. Finally, we demonstrated that reconstructed human gingival epithelium, as a model, was good enough to be proposed as a functional equivalent for native human gingival epithelium in order to study the regulation of gingival innate immunity against periodontal infections.
...
PMID:Antimicrobial peptide modulation in a differentiated reconstructed gingival epithelium. 1721 97
Human organism, constantly exposed to a large variety of pathogenic microorganisms and their products, such as
lipopolysaccharide
(
LPS
), developed innate immunity as a first line of defence. One of the compartments of our organism well equipped with these defence mechanisms is the respiratory system. The cells lining the airways respond to the presence of virulent microorganisms by producing natural antimicrobial peptides, including the only member of the cathelicidins family found to date in humans, peptide
LL-37
.
LL-37
is a small peptide of 37 amino acid residues. The peptide, in addition to its bactericidal effect, plays numerous roles in inflammatory and tissue remodelling processes. It stimulates angiogenesis, induces proliferation of lung epithelial cells, accelerates wound closure of the airway epithelium, and provokes cytokine release (e.g. IL-8) and cell migration.
LL-37
is also able to neutralize
LPS
, a heteropolymer associated with organic dust, produced by Gram-negative bacteria.
LPS
(commonly referred to as endotoxin) plays an important role in pathogenesis of many respiratory diseases caused by organic dust, including organic dust toxic syndrome and chronic illnesses such as chronic obstructive pulmonary disease (COPD), asthma or allergic alveolitis (hypersensitivity pneumonitis).
LPS
is a strong pro-inflammatory stimulus, inducing in respiratory airways expression of antimicrobial peptides, including
LL-37
, which is in turn a potent
LPS
-neutralizing factor. The article discusses the complex interplay between endotoxin and the
LPS
-neutralizing, pleiotropic peptide
LL-37
in pathogenic mechanisms of lung diseases, with regard to closer perspectives of using
LL-37
and its derivatives as therapeutic agents.
...
PMID:Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide. 1765 71
The antimicrobial peptide
LL-37
is generated from skin keratinocytes during infection of Gram-negative bacteria and exerts a microbicidal effect.
LL-37
also causes functional changes in mast cells. Mast cells in the skin are involved in the innate immune system response against microbial infections via Toll-like receptors (TLRs), such as TLR4, which that is known to recognize
lipopolysaccharide
(
LPS
), a bacterial component. Thus, in the present study, we examined the effects of
LL-37
on the expression of TLRs and the generation of cytokines on mast cells, and considered functional changes in the host defense system against bacteria. We observed that
LL-37
increased the level of TLR4 mRNA and TLR4 protein, and that
LL-37
induced the release of IL-4, IL-5 and IL-1beta from mast cells. Cross-interaction between
LL-37
-triggered TLR4 augmentation and
LL-37
-inducible cytokine generation was also examined. Although the up-regulation of
LL-37
-inducible Th2 cytokines was cancelled by
LPS
, the augmentation of pro-inflammatory cytokine production was still observed. These findings indicate that
LL-37
co-existing with the bacterial component switches mast cell function and directs human mast cells toward innate immunity. In conclusion,
LL-37
may be a candidate modifier of the host defense against bacterial entry by serving as an alarm for sentinels such as mast cells.
...
PMID:Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity. 1823 75
Bactericidal/permeability-increasing protein (BPI) is a
cationic antimicrobial protein
produced by polymorphonuclear leukocytes, that specifically interacts with and kills Gram-negative bacteria. BPl competes with lipopolysaccharide-binding protein (LBP) secreted by liver cells into blood plasma for binding to
lipopolysaccharide
(
LPS
) and thus reduces the proinflammatory effects of
LPS
. We have developed a time-resolved fluoroimmunoassay for BPI and measured the concentration of BPI in human serum and plasma samples. The assay is based on a rabbit antibody against recombinant BPI. This antibody specifically adheres to polymorphonuclear leukocytes in immunostained human tissues. The difference in the serum concentration of BPI between unselected hospitalized patients with and without an infection was statistically significant. The mean concentration of BPI in serum samples was 28.3 mug/l (range 1.64-132, S.D. 26.8, n = 83). In contrast, there was no difference between the two groups in the BPI levels in plasma samples. For all individuals tested, BPI levels were consistently higher in plasma samples compared to the matched serum samples. The mean concentration of BPI in plasma samples was 52.3 mug/l (range 0.9-403, S.D. 60.6, n = 90). There was a positive correlation between the concentration of BPI and the white blood cell count as well as between the BPI concentration and C-reactive protein (CRP) in serum samples. In conclusion, the present study demonstrates that BPI can be quantified reliably by time-resolved fluoroimmunoassay in human serum samples.
...
PMID:Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing protein. 1847 97
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>